Manidipina Aurobindo

Manidipine Dihydrochloride, the active ingredient in Manidipina Aurobindo, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure in adult patients with hypertension by relaxing vascular smooth muscle.\n\nGNH India supplies Manidipina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across the European Union and other global markets. The product meets EU quality standards and is manufactured under strict GMP conditions.

Manidipine is a calcium channel blocker indicated for the management of hypertension.\n\nEssential hypertension: lowers systolic and diastolic pressure in patients with primary hypertension.\nIsolated systolic hypertension: provides arterial vasodilation to reduce elevated systolic pressure.\nHypertension in elderly patients: improves blood pressure control with once‑daily dosing.

Manidipine may cause adverse reactions that vary in frequency and severity.\n\nCommon Side Effects:\n- Headache\n- Flushing\n- Peripheral edema\n- Dizziness\n\nSerious or Rare Side Effects:\n- Severe hypotension\n- Angioedema\n- Hepatic enzyme elevation

Before initiating therapy, several safety considerations should be observed.\n\nMonitor blood pressure: measure regularly after starting treatment.\nAssess renal function: adjust use in patients with severe renal impairment.\nCaution in hepatic disease: use with care in liver dysfunction.\nAvoid abrupt discontinuation: taper to prevent rebound hypertension.\nStore at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Manidipine can interact with other medicines, requiring attention to avoid adverse outcomes.\n\nMajor Interactions (Avoid):\n- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels.\n- Co‑administration with other antihypertensives (e.g., ACE inhibitors) can cause excessive hypotension.\n- Use with grapefruit juice: can elevate drug concentration.\n\nModerate Interactions (Monitor Closely):\n- Non‑dihydropyridine calcium channel blockers (e.g., verapamil): may enhance cardiac effects.\n- Diuretics: may increase risk of electrolyte imbalance and hypotension.